Repligen (NASDAQ:RGEN) issued an update on its FY 2020
Pre-Market earnings guidance on Thursday morning. The company provided earnings per share guidance of 1.24-1.29 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $1.13. The company issued revenue guidance of $332-340 million, compared to the consensus revenue estimate of $317.04 million.Repligen also updated its FY20 guidance to $1.24-1.29 EPS.
Shares of Repligen stock opened at $150.91 on Friday. The company has a debt-to-equity ratio of 0.25, a current ratio of 15.56 and a quick ratio of 14.09. Repligen has a 1 year low of $72.32 and a 1 year high of $155.27. The company has a market capitalization of $7.91 billion, a P/E ratio of 126.04, a P/E/G ratio of 5.43 and a beta of 1.06. The business has a 50 day moving average price of $125.27 and a 200 day moving average price of $111.55.
Repligen (NASDAQ:RGEN) last issued its quarterly earnings data on Thursday, July 30th. The biotechnology company reported $0.42 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.28 by $0.14. The firm had revenue of $87.46 million during the quarter, compared to the consensus estimate of $78.11 million. Repligen had a return on equity of 5.99% and a net margin of 10.23%. As a group, research analysts expect that Repligen will post 1.26 EPS for the current fiscal year.
Several analysts have commented on the stock. Stifel Nicolaus lifted their target price on shares of Repligen from $135.00 to $150.00 and gave the stock a buy rating in a research note on Wednesday, May 27th. HC Wainwright reaffirmed a buy rating and issued a $151.00 target price (up from $143.00) on shares of Repligen in a research note on Tuesday, June 30th. SVB Leerink lifted their target price on shares of Repligen from $115.00 to $150.00 and gave the stock an outperform rating in a research note on Thursday, May 7th. BidaskClub raised shares of Repligen from a buy rating to a strong-buy rating in a research note on Saturday, July 25th. Finally, Craig Hallum lifted their target price on shares of Repligen from $120.00 to $145.00 and gave the stock a buy rating in a research note on Thursday, May 7th. Two analysts have rated the stock with a hold rating, five have given a buy rating and two have given a strong buy rating to the company’s stock. The stock has an average rating of Buy and an average price target of $136.67.
In related news, CEO Anthony Hunt sold 46,953 shares of Repligen stock in a transaction on Thursday, May 21st. The shares were sold at an average price of $139.77, for a total transaction of $6,562,620.81. Following the transaction, the chief executive officer now owns 238,157 shares in the company, valued at approximately $33,287,203.89. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Ralf Kuriyel sold 435 shares of Repligen stock in a transaction on Friday, May 15th. The shares were sold at an average price of $140.69, for a total transaction of $61,200.15. Following the transaction, the vice president now owns 26,089 shares in the company, valued at approximately $3,670,461.41. The disclosure for this sale can be found here. Insiders have sold a total of 92,264 shares of company stock valued at $12,168,083 over the last three months. Corporate insiders own 1.70% of the company’s stock.
Repligen Company Profile
Repligen Corporation develops, manufactures, and sells products used to enhance the interconnected phases of the biological drug manufacturing process in North America, Europe, APAC, and internationally. It offers Protein A ligands to life sciences companies, which are the binding components of Protein A affinity resins; and growth factor products used to supplement cell culture media.
Featured Story: How to interpret the current ratio
Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.